Twitter Logo Youtube Circle Icon LinkedIn Icon

China > Healthcare and life sciences > Law firm and leading lawyer rankings

Editorial

Healthcare and life sciences: foreign firms

Index of tables

  1. Healthcare and life sciences: foreign firms
  2. Leading individuals
  3. Next Generation Partners

Leading individuals

  1. 1
    • Geoffrey Lin - Ropes & Gray LLP
    • Katherine Wang - Ropes & Gray LLP

Next Generation Partners

  1. 1

CMS is singled out for its 'excellent knowledge of industry and local regulatory framework'. The practice advises on corporate and commercial, IP, regulatory, transfer pricing, competition and anti-corruption mandates. Its client roster features a number of well-known pharmaceutical and medical devices companies; Takeda Pharmaceutical Company, Smith & Nephew, Boehringer-Ingelheim and Bayer are among the list. Nick Beckett, who jointly leads the global life sciences and healthcare sector group with Jens Wagner in Germany, is 'particularly strong in his relationship management with clients and understanding client business and needs'. Beckett advised a medical device manufacturing company on the establishment of a joint venture with its supplier and advised a Chinese biopharmaceutical company on the freedom to operate searches on a number of its products. Nicolas Zhu advised a multinational animal healthcare company on regulatory and compliance issues including advertising in China, regulatory issues relating to import and distributions.

Ropes & Gray LLP's transactional team has been particularly active, given preferential government policy regarding the advancement of the life sciences industry; it continues to handle a steady stream of high-profile compliance and FCPA cases, as well as IP transactions and disputes. The full-service life sciences team is led by transactional lawyer Arthur Mok, which also includes IP specialists Geoffrey Lin and counsel David Chen, Katherine Wang and new partner David Zhang who focus on regulatory and FCPA matters respectively. A multi-jurisdictional team assisted Zai Lab with its $172m IPO at NASDAQ as well as its pre-IPO cross-over financing led by OrbiMed and Vivo Capital, and advised Profex on its joint acquisition with Morgan Stanley Private Equity Asia of Korres SA Natural Products. The IP team assisted Simcere Pharmaceutical Group with its collaboration with Merus to obtain an exclusive license to develop and commercialise three bispecific antibodies using Merus' Biclonics technology platform in immune-oncology. Other highlights saw the team advising medtech companies with the formation of collaboration and joint ventures.

Baker McKenzie FenXun's mainland China healthcare group works closely with its Hong Kong office. It has particular expertise in IP, M&A, dispute resolution and regulatory/compliance matters. Recent highlights include advising a Chinese healthcare company on its collaboration with a US healthcare institution and acting for a US company on product labelling and trade mark use to meet regulatory changes to infant formula and formula food for special medical purpose. Clement Ngai is a key contact within its cross-office team and is recommended for IP due diligence, licensing, clinical trial agreements, product liability and recalls. Ngai handled an administrative investigation relating to the use and sale of food products having a non-food ingredient and illegal food additives. Vivian Wu is assisting a Fortune 500 medical devices manufacturer with a series of internal investigations in relation to an alleged bribery action. Hong Kong-based Isabella Liu and Tracy Wut are also names to note.

Covington & Burling LLP  is also ranked.

Hogan Lovells International LLP is a popular choice among the leading global pharmaceutical and life sciences sector clients. The team covers the full spectrum of life sciences matters, with particular strength in regulatory issues and big-ticket M&A transactions. LabCorp is a prominent client which the team represents in a range of matters; in 2017, Jun Wei was part of a global team that advised LabCorp on its $1.2bn acquisition of Chiltern. Roy Zou and senior associate Jessie Xie assisted Dr Pepper Snapple Group with regulatory issues relating to the labels and formulas of one of its beverage lines. Zou also assisted an international medical device company with responding to a China Food and Drug Administration (CFDA) investigation relating to the failing of Chinese compliance requirement. Andrew McGinty is advising a US start-up company on its joint venture with a Chinese institutional investor for its clinical trials in China. Eugene Chen handled a significant anti-bribery investigation and is acting for a multinational pharmaceutical company in an anti-bribery compliance due diligence investigation pertaining a proposed establishment of a joint venture with a Chinese state-owned company.

Morrison & Foerster LLP is singled out for its expertise in the IP space, spanning prosecution, litigation and licensing. The team assisted Henlius with its collaboration and licensing agreement with Galaxy Biotech, a clinical stage biotechnology company focused on discovering and developing novel humanised antibodies for the treatment of cancer and advised an emerging cancer treatment company on its patent portfolio management. The team is also particularly in the M&A and private equity investment sphere, and recently advised a sovereign wealth fund on its multimillion-dollar financing in an antibody and biotherapeutics developing company. Gordon Milner and Chuan Sun are the key names to note in its Hong Kong office. Palo Alto-based Janet Xiao co-chairs the global life sciences group and is regularly instructed on China-related IP matters for biotechnology and pharmaceutical sector clients.

Sidley Austin LLP  is also ranked.

Allen & Overy LLP's China healthcare team includes practice head David Shen, who has particular expertise in the life sciences sector and in handling IP aspect of M&A and other corporate transactions, and corporate partner Jack Wang who joined from Freshfields Bruckhaus Deringer in 2018. The managing partner of its Beijing and Shanghai office, Victor Ho, has broad corporate and M&A experience including joint ventures, stock mergers, private stock and asset purchases, and private placements. The team recently assisted a number of multinational pharmaceutical giants with defending the validity of their patents in China and advised a biotech company in setting up a joint venture and acquiring the Chinese rights to drug candidates from third-party pharmaceutical companies.

Bird & Bird is praised for its 'pragmatic and business-oriented approach'. Leveraging its strong focus in the technology-driven sectors, the firm is particularly active in advising mobile health and medical devices companies on IP, data protection, investment and IP issues. In the life sciences space, it has experience in the full business cycle of products and services, from R&D collaborations and clinical trials to IP licensing and transactions. Alison Wong heads the Asia Pacific life sciences and healthcare group from its Hong Kong office, and is recommended for IP, clinical trials, procurement and regulatory matters. Working with its associated Chinese firm Lawjay Partners, the team represented Shenzhen Mindray Bio-Medical Electronics in a retrial proceeding pertaining to a patent invalidation administrative litigation before the Supreme People's Court. IP litigation specialist Christine Yiu is also recommended.

Cooley LLP is known for representing life sciences sector clients and private investors on corporate partnering, licensing and M&A transactions. The team recently advised BAHEAL Intelligence Technology of China on its establishment of an alliance with artificial intelligence company IBM Watson Health, and assisted Advantech Master Investment with its $76m series A investment in KBP Biosciences. Christina Zhang and James Lu are the main contacts.

DLA Piper handles a mix of transactional and regulatory mandates for a number of global pharmaceutical, biotechnology and medical devices companies. Roy Chan and James Chang advised Ping An Healthcare and Technology Company on its pre-IPO restructuring; Chan was also part of a multi-jurisdictional team that advised China Ping An Insurance Overseas on its Chinese joint venture with Tsumura & Co. Shanghai-based Qiang Li assisted Sanpower Group with its $820m acquisition of Dendreon Pharmaceuticals. The team expanded with the arrival of William Fisher from Hogan Lovells International LLP who focuses on patents, trade secrets and IP-related transactions.


Healthcare and life sciences: PRC firms

Index of tables

  1. Healthcare and life sciences: PRC firms
  2. Leading individuals
  3. Next Generation Partners

Leading individuals

  1. 1

Next Generation Partners

  1. 1

Fangda Partners' client roster is diversified, ranging from large and medium-sized pharmaceutical companies, medical device manufacturers, distribution groups, contract research organisations, to private equity funds and venture capitals. Among its recent mandates, Fang Qi represented Watson Pharmaceuticals in its infringement dispute with another international pharmaceutical company regarding patent for the treatment of Schizophrenia; Qi also advised APBI in a patent administrative case concerning the validity of its patent for Dapoxetine at the Beijing High Court and the Supreme Court. On the transactional side, Josh Shin and Yang Gao advised Astra Zeneca in its granting to China Medical System of exclusive commercialisation rights of Plendil in China. Shin and Diana Li also assisted Wuxi Biologics with its IPO at the HKEX and handled Everbright's share acquisition of Lifetech Scientific (Shenzhen) from Medtronics. Kate Yin is singled out for her expertise in handling compliance and regulatory matters as well as internal investigations.

Global Law Office's 'go-to' department excels in handling financing, M&A, reform and restructuring of public hospitals and regulatory mandates. The team, led by Alan Zhou, is a 'clear market leader in the healthcare and life sciences sphere' and is singled out for its 'fast response and commercially-minded advice'. Zhou 'fully understands the industry', and gives 'timely and operative response'. Coco Fan has notable knowledge in the medical, biopharmaceutical and animal health industries. Robert Sun, Michael Yu and David Fu are key names to note, as is anti-corruption specialist Jacky Li. The team acted as PRC counsel for BeiGene in its $1.4bn acquisition of Celgene China Entity, handled Siemens Healthineers' restructuring of China healthcare business and advised GP Health Service Capital on its RMB200m investment in Beaucare's series B financing. GlaxoSmithKline, ChunYu Doctor, Zeiss and Shanghai Pharmaceuticals also feature in its impressive client list.

King & Wood Mallesons is regularly instructed on the largest transactions in the China market; in 2017, the team advised LuyePharma Hong Kong on its purchase of Astra Zeneca's Seroquel and Seroquel XR in the UK, China and other 49 international markets and assisted a number of US and Chinese investors in the sales and purchases of pharmaceutical and medical devices companies. Other instructions include acting for an investment fund in financing for a medical device company and assisting a Chinese pharmaceutical company with compliance issues relating to the IPO approval by the Securities Regulatory Commission. The sizable group is led by transaction lawyers Jianping Wang and Jianwen Huang which also includes patent specialist Wenping Chen. Senior associate Yuanyuan Zhu is also a recommended practitioner with particular expertise in compliance and investigation.

Han Kun Law Offices is regularly instructed by major funds in their significant healthcare sector investments in China. It also handles compliance and regulatory issues and has particular expertise in competition law, IP and litigation. Among its recent highlights, the team assisted a global pharmaceutical company with a compliance investigation, and advised a dental service chain in a financing mandate. IP specialist Yan Wang represented SMTP Technology in a series of patent infringement and invalidation disputes against Sonicmed Medical Technology. Charles Li is recommended for public and private financing, corporate restructuring and IP protection; Shanghai-based Min Zhu and Kelvin Gao focus on the formation and deployment of private equity funds, M&A and corporate matters.

Zhong Lun Law Firm advises pharmaceutical companies and healthcare providers on corporate, securities and regulatory matters. The team also has experience handling IP disputes and licensing transactions, Shanghai-based Helen Cheng is a key name to note. Cheng recently represented a Chinese biotech company in defending two patent infringement cases filed by a foreign company at the Beijing Intellectual Property Court and assisted Chiral Quest (Suzhou) with a series of technology license agreements and a patent ownership dispute against Zhejiang Changming Pharmaceutical. Its recent transactional mandates including advising C-Bridge Capital on its financing for CMAB Biopharma and advised Shenzhen Hepalink Pharmaceutical Group on its share purchase of Shenzhen Topknow Industry and Development.

JunHe LLP specialises in major institutional investors mandates, with capability of handling regulatory, IP and contentious matters. The team includes Fan Yang who advises life sciences and healthcare sector clients as well as private equity funds; Xudong Tao whose expertise lies in the formation and restructuring of companies and private equity funds; and Feng Zhou who is experienced in handling high-profile M&A transactions. The team handled a number of M&A and joint venture mandates.

Llinks Law Offices leverages its strength in capital markets to advise on a mix of listing, financing and M&A transactions for multinational and domestic pharmaceutical clients; it also advises on IP protection, cybersecurity and data protection issues. The team assisted a consortium of institutional investors with their investment in Eyebright, a leading Chinese ophthalmic medical company, and advised Elemental Concept 2016 on cybersecurity and data protection issues in relation to the development, licensing, and operation of medical record system for hospitals in China. Wayne Chen and David Yu are names to note.


Press releases

The latest news direct from law firms. If you would like to submit press releases for your firm, send an email request to

Legal Developments in China

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to

Press Releases worldwide

The latest news direct from law firms. If you would like to submit press releases for your firm, send an email request to